Wednesday, September 14, 2016 9:17:16 PM
* Glatopa scripts represent 38% of the 20 mg glatiramer acetate
market in the U.S.
• Estimated annual cost savings in 2016 for Glatopa 20 mg
versus the daily COPAXONE 20 mg dose is ~$17k per patient
based on US wholesale acquisition costs
If the price savings is truly $17K per patient annually, I'm surprised they only have 38% of the available market.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM